<DOC>
	<DOCNO>NCT00028652</DOCNO>
	<brief_summary>RATIONALE : Inserting gene interleukin-12 person 's skin tumor cell may make body build immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness interleukin-12 gene therapy treat patient skin metastasis .</brief_summary>
	<brief_title>Interleukin-12 Gene Therapy Treating Patients With Skin Metastases</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety toxicity interleukin-12 gene patient spontaneous skin metastasis . - Determine antitumor immune response patient treat regimen . - Compare toxicity regimen administer 1 week vs 2 week patient . - Compare local systemic antitumor response patient treat regimen administer 1 week vs 2 week . OUTLINE : Patients stratify accord number tumor site ( 1 vs 2 v 3 ) . Patients assign 1 2 treatment arm . - Group A : Patients receive interleukin-12 gene intratumorally 5 minute day 1 , 3 , 5 . - Group B : Patients receive IL-12 gene intratumorally 5 minute day 1 , 3 , 5 , 8 , 10 , 12 . Patients stable respond disease may receive 1 subsequent course begin day 29 . Patients follow 3 , 6 , 12 month . PROJECTED ACCRUAL : A total 12 patient ( 6 per treatment group ) accrue study .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid malignancy Surgically medically incurable disease No standard chemotherapy radiotherapy exist disease Tumor least 0.5 cm 2.5 cm infiltrate underlying skin Cutaneous metastasis , subcutaneous metastasis , tumorinvolved lymph node easily palpable PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : More 3 month Hematopoietic : WBC great 3,000/mm^3 Platelet count great 80,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL Renal : Creatinine le 2.0 mg/dL Other : HIV negative No active infection require antibiotic , antiviral , antifungal treatment No active malignancy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 month since prior immunotherapy No concurrent colonystimulating factor Chemotherapy : See Disease Characteristics At least 1 month since prior chemotherapy Endocrine therapy : At least 1 month since prior steroid ( intermittent use antiemetic topical agent ) No concurrent steroid Radiotherapy : See Disease Characteristics Prior radiotherapy vaccine site allow provided documentation progressive disease Surgery : See Disease Characteristics No prior organ allografts Other : No concurrent antineoplastic therapy No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>skin metastasis</keyword>
</DOC>